Abstract:Programmed cell death protein-1 (PD-1) is a vital immune checkpoint molecule. The location, stability, and protein–protein interaction of PD-1 are significantly influenced by post-translational modification (PTM) of proteins. The biological information of PD-1, including its gene and protein structures and the PD-1/PD-L1 signaling pathway, was briefly reviewed in this review. Additionally, recent research on PD-1 post-translational modification, including the study of ubiquitination, glycosylation, phosphorylation, and palmitoylation, was summarized, and research strategies for PD-1 PTM drugs were concluded. At present, only a part of PD-1/PD-L1 treated patients (35–45%) are benefited from immunotherapies, and novel strategies targeting PTM of PD-1/PD-L1 may be important for anti-PD-1/PD-L1 non-responders (poor responders).
What problem does this paper attempt to address?
The problem that this paper attempts to solve is about the potential role of post - translational modification (PTM) of programmed death receptor - 1 (PD - 1) in tumor immunotherapy. Specifically, the paper explores several major post - translational modifications of PD - 1, including ubiquitination, glycosylation, phosphorylation and palmitoylation, and how these modifications affect the function of PD - 1 and its application potential in tumor immunotherapy. The paper also discusses drug development strategies targeting PD - 1 post - translational modifications to improve the efficacy of immune checkpoint inhibitors (such as anti - PD - 1 monoclonal antibodies), especially for those patients who have a poor response to existing PD - 1/PD - L1 treatments.
### Main problems:
1. **Biological effects of PD - 1 post - translational modifications**:
- **Ubiquitination**: Ubiquitination mediated by E3 ligases (such as FBXO38, KLH22, c - Cbl, FBW7) can reduce the expression of PD - 1, thereby decreasing its level on the T - cell surface and enhancing the anti - tumor immune response.
- **Glycosylation**: Glycosylation at the N - glycosylation sites (N49, N58, N74, N116) of PD - 1 can increase the affinity between PD - 1 and PD - L1 and improve its stability. Changes in glycosylation may affect the binding ability of anti - PD - 1 antibodies.
- **Phosphorylation**: Phosphorylation of the tyrosine residues (Y223, Y248) of PD - 1 can inhibit the T - cell receptor (TCR) signaling pathway, thereby inhibiting the proliferation and activation of T - cells. SHP1 and SHP2 proteins regulate this process by dephosphorylating the ITIM and ITSM domains of PD - 1.
- **Palmitoylation**: Palmitoylation of PD - 1 (such as at the Cys192 site) can promote its localization in recycling endosomes, prevent its degradation through the lysosomal pathway, and thus maintain its level on the cell surface.
2. **Drug development for PD - 1 post - translational modifications**:
- **Targeting ubiquitination**: Research on the discovery and screening of E3 ligases, and the development of small - molecule inhibitors of E3 ligases to regulate the ubiquitination level of PD - 1.
- **Targeting glycosylation**: Development of antibodies targeting PD - 1 N - glycosylation sites, such as cemiplimab, penpulimab and camrelizumab.
- **Targeting phosphorylation**: Research on SHP2 allosteric inhibitors, such as PB17 - 026 - 01 and SHP099, to overcome drug resistance caused by SHP2 mutation or inactivation.
- **Targeting palmitoylation**: Development of small - molecule inhibitors of DHHC9 to block the palmitoylation of PD - 1, thereby inhibiting tumor growth.
3. **Bispecific antibodies and other novel therapies**:
- The paper also discusses the development of bispecific antibodies, such as tebotelimab (PD - 1 × LAG - 3), cadonilimab (PD - 1 × CTLA - 4), and other bispecific antibodies in clinical trials, such as MEDI5752, IBI319, LY3434172, MGD019 and CDX - 527.
- Precision medicine strategies are also mentioned, that is, formulating personalized treatment plans according to the individual characteristics of patients to improve the treatment effect.
Through these studies, the paper aims to provide theoretical and experimental bases for the development of more effective PD - 1 - targeted therapies, especially in improving the treatment effect of non - responders (i.e., patients with a poor response to existing PD - 1/PD - L1 treatments).